Walvax Biotechnology Co (SZSE:300142) COGS-to-Revenue : 0.19 (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Walvax Biotechnology Co COGS-to-Revenue?

Walvax Biotechnology Co's Cost of Goods Sold for the three months ended in Mar. 2024 was ¥114 Mil. Its Revenue for the three months ended in Mar. 2024 was ¥600 Mil.

Walvax Biotechnology Co's COGS to Revenue for the three months ended in Mar. 2024 was 0.19.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Walvax Biotechnology Co's Gross Margin % for the three months ended in Mar. 2024 was 81.07%.

Walvax Biotechnology Co COGS-to-Revenue Historical Data

The historical data trend for Walvax Biotechnology Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Walvax Biotechnology Co COGS-to-Revenue Chart

Walvax Biotechnology Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.20

0.14

0.11

0.12

0.15

Walvax Biotechnology Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.15	0.11	0.18	0.15	0.19

Walvax Biotechnology Co COGS-to-Revenue Calculation

Walvax Biotechnology Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	597.556	/	4113.772
	=	0.15

Walvax Biotechnology Co's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	113.519	/	599.754
	=	0.19

Walvax Biotechnology Co (SZSE:300142) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Walvax Biotechnology Co's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	113.519 / 599.754
	=	81.07 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Walvax Biotechnology Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Walvax Biotechnology Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Walvax Biotechnology Co (SZSE:300142) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Walvax Biotechnology Co Ltd (SZSE:300142) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

Keyuan Road No. 99, 19th Floor, Building 9A, Dingyi Tiancheng Residential Quarter, High & New Tech Development Zone, Yunnan Province, Kunming, CHN, 650106

Website

http://www.walvax.com

Walvax Biotechnology Co Ltd biological pharmaceutical enterprise engaged in research and development, production and sales of bio-medicine products. It offers bio-medicines, such as vaccines, blood products, and others. The company's products include Haemophilus influenza type b conjugate vaccines, freeze-dried group A, C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines, and group A and C meningococcal polysaccharide vaccines.

Walvax Biotechnology Co (SZSE:300142) Headlines

No Headlines